Company: MISSION Therapeutics
Job title: Chief Scientific Officer
Paul has over 15 years of experience in translational research and early clinical development. Before joining Mission as Medical Director for CNS, Paul worked as a Clinical Science Director at ONO Pharma UK, leading clinical development of multiple early phase assets across a variety of indications including inflammatory pain, portal hypertension, whilst driving translational strategies for preclinical programs. Prior to this, Paul spent 12 years at GlaxoSmithKline, transitioning from laboratory biomarker research, through experimental medicine study leadership, to leading global project teams as Director of Discovery Medicine in the Neurology TA.
Paul is a member of the British Pharmacological Society and American Academy of Neurology and is an industry tools consortium member with the Michael J Fox Foundation.
Paul holds an MBiochem from the University of Oxford and a PhD from UCL.
USP30 inhibitors: Releasing the Brakes to Improve Mitochondrial Quality Control During Disease 2:15 pm
• Consider how USP30 is the only mitochondrial deubiquitylating enzyme, perfectly placed to regulate mitochondrial ubiquitin and quality control • Examine USP30 inhibitor target engagement and how pharmacodynamics can be followed in-vivo • Explore Multiple disease pathologies and how they are prevented/reversed by USP30 inhibitorsRead more
day: Day One